Filing Analysis
Other SEC Filing
Filed May 06, 2026
LOW
Actuate Therapeutics expanded its board to eight members and appointed Dr. Martin H. Huber, a veteran oncology executive, as a Class III director. Dr. Huber will also provide research and development advisory services under a separate consulting agreement.
Red Flags
- Potential related-party conflict: The director is receiving additional consulting fees ($12,000/year) beyond standard board compensation.
Key Facts
- Appointed Martin H. Huber, MD, to the Board of Directors effective May 1, 2026.
- Board expanded from seven to eight members to accommodate the new appointment.
- Dr. Huber will receive an annual retainer of $44,000 and an initial grant of 30,000 stock options vesting over three years.
- Entered into a consulting agreement with Dr. Huber for R&D advisory services at $3,000 per quarter.
- Dr. Huber previously served as CEO of Mersana Therapeutics and CMO of TESARO (acquired by GSK).
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.